FrancophonIA/ELRC3.0 huggingface dataset:
English: For co-administration of efavirenz with low-dose ritonavir in combination with a protease inhibitor, see section on ritonavir below.
Slovenian: Za sočasno uporabo efavirenza in majhnih odmerkov ritonavirja v kombinaciji z zaviralci proteaze glejte poglavje o ritonavirju spodaj.
English: - if you are allergic to efavirenz, emtricitabine, tenofovir, tenofovir disoproxil or any of the other ingredients of this medicine (listed in section 6).
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Atripla Ne jemljite zdravila Atripla - če ste alergični na efavirenz, emtricitabin, tenofovir, dizoproksiltenofovirat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: AUC: ↔ Cmax: ↓ 19% (↓ 40 to ↑ 10)
Slovenian: Cmax: ↓ 19 % (↓ 40 do ↑ 10)
English: AUC: ↓ 35% (↓ 13 to ↓ 40) Cmax: ↓ 13% (↓ 0 to ↓ 23)
Slovenian: AUC: ↓ 35 % (↓ 13 do ↓ 40) Cmax: ↓ 13 % (↓ 0 do ↓ 23)
English: AUC: ↔ Cmax: ↑ 38% (↑ 14 to ↑ 67)
Slovenian: Cmax: ↑ 38 % (↑ 14 do ↑ 67)
English: Recommendation concerning co-administration with Atripla (efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Slovenian: Priporočilo glede sočasne uporabe z zdravilom Atripla (efavirenz 600 mg, emtricitabin 200 mg,
English: • fatty liver
Slovenian: • suha usta;
English: GMR (%) (90%CI)
Slovenian: n/N ( %)
English: AUC: ↓ 71% (↓ 67 to ↓ 74) Cmax: ↓ 51% (↓ 46 to ↓ 56) Cmin: ↓ 91% (↓ 88 to ↓ 92)
Slovenian: AUC: ↓ 71 % (↓ 67 do ↓ 74) Cmax: ↓ 51 % (↓ 46 do ↓ 56) Cmin: ↓ 91 % (↓ 88 do ↓ 92)
English: AUC: ↓ 4% (↓ 0 to ↓ 31) Cmax: ↓ 47% (↓ 9 to ↓ 51)
Slovenian: AUC: ↓ 4 % (↓ 0 do ↓ 31) Cmax: ↓ 47 % (↓ 9 do ↓ 51)
English: ANTICOAGULANTS Warfarin/Efavirenz Acenocoumarol/Efavirenz
Slovenian: varfarin/efavirenz acenokumarol/efavirenz
English: Caution must be taken in any patient with a history of seizures.
Slovenian: Pri vseh bolnikih z epileptičnimi napadi v anamnezi je potrebna previdnost.
English: Prior PI-based regimen (N=34)
Slovenian: Predhodno zdravljenje z ZP (N = 34)
English: However, dizziness has been reported during treatment with efavirenz, emtricitabine and tenofovir disoproxil.
Slovenian: Vendar so med zdravljenjem z efavirenzom, emtricitabinom in dizoproksiltenofoviratomporočali o omotici.
English: Rosuvastatin/Emtricitabine
Slovenian: rosuvastatin/emtricitabin
English: AUC: ↓ 58% (↓ 39 to ↓ 68) Cmax: ↓ 51% (↓ 32 to ↓ 58)
Slovenian: AUC: ↓ 58 % (↓ 39 do ↓ 68) Cmax: ↓ 51 % (↓ 32 do ↓ 58)
English: AUC: ↔ Cmax: ↓ 23% (↓ 30 to ↑ 16)
Slovenian: Cmax: ↓ 23 % (↓ 30 do ↑ 16)
English: Reproductive system and breast disorders: Uncommon gynaecomastia
Slovenian: Motnje reprodukcije in dojk: Občasni ginekomastija
English: Switching from a PI-based antiretroviral regimen
Slovenian: Prehod od režima protiretrovirusnega zdravljenja na osnovi zaviralcev proteaz (ZP)
English: These patients should be carefully monitored for rises in viral load and, since the safety profile of efavirenz differs from that of protease inhibitors, for adverse reactions.
Slovenian: Ker se profil varnosti efavirenza razlikuje od profila varnosti zaviralcev proteaz je treba bolnike nadzirati tudi glede pojava neželenih reakcij.
English: Methadone/Emtricitabine
Slovenian: metadon/emtricitabin
English: The safety and efficacy of Atripla in children under the age of 18 years have not been established (see section 5.2).
Slovenian: Varnost in učinkovitost zdravila Atripla pri otrocih starih do 18 let še nista bili dokazani (glejte poglavje
English: Artemether/Lumefantrine/Tenofovir disoproxil
Slovenian: artemeter/lumefantrin/ dizoproksiltenofovirat
English: In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Slovenian: Mogoče bo upravičena ponovna uvedba zdravljenja hepatitisa B. Pri bolnikih z napredovalo jetrno boleznijo ali cirozo jeter prekinitev zdravljenja ni priporočljiva, poslabšanje hepatitisa po zdravljenju namreč lahko povzroči jetrno dekompenzacijo.
English: No dose recommendation can be made for the use of Atripla with carbamazepine.
Slovenian: Za kombinacijo zdravila Atripla in karbamazepina ni mogoče dati priporočila za odmerjanje.
English: There were no clinically significant pharmacokinetic interactions when efavirenz was administered with azithromycin, cetirizine, fosamprenavir/ritonavir, lorazepam, nelfinavir, zidovudine, aluminium/magnesium hydroxide antacids, famotidine or fluconazole.
Slovenian: Pri sočasni uporabi efavirenza in azitromicina, cetirizina, fosamprenavirja/ritonavirja, lorazepama, nelfinavirja, zidovudina, antacidov, ki vsebujejo aluminijev/magnezijev hidroksid, famotidina ali flukonazola, ni bilo klinično pomembnih farmakokinetičnih interakcij.
English: Co-administration with voriconazole.
Slovenian: Sočasna uporaba z vorikonazolom.
English: Elderly Atripla should be administered with caution to elderly patients (see section 4.4).
Slovenian: Starejši Pri starejših bolnikih je treba zdravilo Atripla uporabljati previdno (glejte poglavje 4.4).
English: Insufficient data are available to make a dosing recommendation for saquinavir/ritonavir when dosed with Atripla.
Slovenian: Ni na voljo dovolj podatkov, da bi lahko izdelali priporočilo za odmerjanje sakvinavirja/ritonavirja ob sočasni uporabi z zdravilom Atripla.
English: AUC: ↓ 39% (↓ 30 to ↓ 46) Cmax: ↓ 26% (↓ 15 to ↓ 35)
Slovenian: AUC: ↓ 39 % (↓ 30 do ↓ 46) Cmax: ↓ 26 % (↓ 15 do ↓ 35)
English: Selective Serotonin Reuptake Inhibitors (SSRIs) Sertraline/Efavirenz (50 mg q.d./600 mg q.d.)
Slovenian: Selektivni zaviralci ponovnega privzema serotonina (SSRI) sertralin/efavirenz (50 mg dnevno/600 mg dnevno)
English: There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, nelfinavir or ribavirin.
Slovenian: Klinično pomembnih farmakokinetičnih interakcij prav tako ni bilo pri sočasni uporabi dizoproksiltenofovirata in emtricitabina, nelfinavirja ali ribavirina.
English: False-positive urine cannabinoid test results have been reported with some screening assays in uninfected and HIV infected subjects receiving efavirenz.
Slovenian: Pri nekaterih presejalnih testih, izvedenih pri neokuženih prostovoljcih in prostovoljcih, okuženih z virusom HIV, ki so dobivali efavirenz, so poročali o lažno pozitivnih kanabinoidnimi urinskih testih.
English: The following side effects are rare (these may affect up to 1 in every 1,000 patients):
Slovenian: Naslednji neželeni učinki so redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov):
English: Emtricitabine:
Slovenian: emtricitabin:
English: Methadone/Tenofovir disoproxil (40-110 mg q.d./245 mg q.d.)
Slovenian: metadon/ dizoproksiltenofovirat (40-110 mg dnevno/245 mg dnevno)
English: Vigabatrin/Tenofovir disoproxil Gabapentin/Tenofovir disoproxil
Slovenian: vigabatrin/ dizoproksiltenofovirat gabapentin/ dizoproksiltenofovirat
English: Atripla is recommended for administration on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Slovenian: Zdravilo Atripla je priporočljivo jemati na prazen želodec, saj lahko hrana poveča izpostavljenost efavirenzu, kar lahko poveča pogostnost neželenih učinkov (glejte poglavji 4.4 in 4.8).
English: Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days
Slovenian: Na podlagi povezave med koncentracijo in QTc sta pri osebah z genotipom CYP2B6 *6/*6 po 14-dnevni uporabi dnevnega odmerka 600 mg povprečno podaljšanje QTc in zgornja meja njegovega 90-odstotnega intervala zaupanja 8,7 ms oziroma 11,3 ms (glejte poglavje 4.5).
English: AUC: ↓ 75% (↓ 62 to ↓ 84) Cmax: ↓ 44% (↓ 20 to ↓ 61)
Slovenian: AUC: ↓ 75 % (↓ 62 do ↓ 84) Cmax: ↓ 44 % (↓ 20 do ↓ 61)
English: Insufficient data are available to make a dosing recommendation for lopinavir/ritonavir when dosed with Atripla.
Slovenian: Na voljo ni dovolj podatkov, da bi lahko izdelali priporočilo za odmerjanje lopinavirja/ ritonavirja v kombinaciji z zdravilom Atripla.
English: Efavirenz was not mutagenic or clastogenic in conventional genotoxicity assays.
Slovenian: Na osnovi običajnih študij genotoksičnosti zdravilo efavirenz ni bilo mutageno ali klastogeno.
English: Dose adjustment of warfarin or acenocoumarol may be required when co-administered with Atripla.
Slovenian: Pri sočasni uporabi z zdravilom Atripla bo morda treba prilagoditi odmerek varfarina ali acenokumarola.
English: Rifabutin/Emtricitabine
Slovenian: rifabutin/emtricitabin
English: As a fixed combination, Atripla should not be administered concomitantly with other medicinal products containing the same active components, emtricitabine or tenofovir disoproxil.
Slovenian: Zdravilo Atripla je zdravilo s fiksno kombinacijo odmerkov, zato se ne sme uporabljati sočasno z drugimi zdravili, ki vsebujejo iste učinkovine: emtricitabin ali dizoproksiltenofovirat.
English: Each film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as fumarate).
Slovenian: Ena filmsko obložena tableta vsebuje 600 mg efavirenza, 200 mg emtricitabina in 245 mg dizoproksiltenofovirata (v obliki fumarata).
English: Efavirenz levels may increase on stopping St. John's wort.
Slovenian: Koncentracije efavirenza se lahko ob prekinitvi jemanja šentjanževke povečajo.
English: - Lactic acidosis (excess lactic acid in the blood) is a rare (may affect up to 1 in every 1,000 patients) but serious side effect that can be fatal.
Slovenian: - Laktacidoza (čezmerna količina mlečne kisline v krvi) je redek (pojavi se lahko pri največ 1 od
English: Patients with moderate or severe renal impairment require a dose adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Slovenian: Pri bolnikih z zmerno ali hudo ledvično okvaro je potrebna prilagoditev odmerkov emtricitabina in dizoproksiltenofovirata, ki je ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 5.2).
English: Bupropion/Emtricitabine
Slovenian: bupropion/emtricitabin
English: Mechanism of action and pharmacodynamic effects Efavirenz is an NNRTI of HIV-1.
Slovenian: Efavirenz je NNRTI za HIV-1.
English: Co-administration of saquinavir/ritonavir and Atripla is not recommended.
Slovenian: Sočasne uporabe sakvinavirja/ritonavirja in zdravila Atripla ne priporočamo.
English: Atripla should be administered with caution to patients with mild hepatic impairment (see sections 4.3 and 4.4).
Slovenian: Pri bolnikih z blago jetrno okvaro je treba zdravilo Atripla uporabljati previdno (glejte poglavji 4.3 and 4.4).
English: AUC: ↓ 69% (↓ 55 to ↓ 79) Cmax: ↓ 60% (↓ 50 to ↓ 68) Cmin: ↓ 63% (↓ 44 to ↓ 75)
Slovenian: AUC: ↓ 69 % (↓ 55 do ↓ 79) Cmax: ↓ 60 % (↓ 50 do ↓ 68) Cmin: ↓ 63 % (↓ 44 do ↓ 75)
English: Tacrolimus/Emtricitabine/Tenofovir disoproxil (0.1 mg/kg q.d./200 mg/245 mg q.d.)
Slovenian: takrolimus/emtricitabin/ dizoproksiltenofovirat (0,1 mg/kg dnevno/200 mg/245 mg dnevno)
English: Simvastatin/Emtricitabine
Slovenian: simvastatin/emtricitabin
English: Insufficient data are available to make a dosing recommendation for indinavir when dosed with Atripla.
Slovenian: Na voljo ni dovolj podatkov, da bi lahko izdali priporočila za odmerjanje indinavirja in zdravila Atripla.
English: Simeprevir/Efavirenz (150 mg q.d./600 mg q.d.)
Slovenian: simeprevir/efavirenz (150 mg dnevno/600 mg dnevno)
English: Methadone/Efavirenz (35-100 mg q.d./600 mg q.d.)
Slovenian: OPIOIDI metadon/efavirenz (35-100 mg dnevno/600 mg dnevno)
English: CCR5 antagonist Maraviroc/Efavirenz (100 mg b.i.d./600 mg q.d.)
Slovenian: Antagonist CCR5 maravirok/efavirenz (100 mg dvakrat dnevno/600 mg dnevno)
English: If Atripla is stopped your doctor may recommend that you resume hepatitis B treatment.
Slovenian: Če jemanje zdravila Atripla prekinete, vam bo zdravnik morda priporočil nadaljevanje zdravljenja zaradi hepatitisa B. Morda bo potrebno opravljati krvne preiskave za kontrolo delovanja jeter še štiri mesece po prenehanju zdravljenja.
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).
Slovenian: Pri bolnikih z zmerno ali hudo ledvično okvaro je potrebna prilagoditev intervala odmerjanja emtricitabina in dizoproksiltenofovirata, ki je ni mogoče doseči s kombinirano tableto (glejte poglavji 4.4 in 5.2).
English: - Medicines used to treat infection with the hepatitis C virus: boceprevir, elbasvir/grazoprevir,
Slovenian: - Zdravila za zdravljenje okužb z virusom hepatitisa C: boceprevir, elbasvir/grazoprevir, simeprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voksilaprevir.
English: AUC: ↓ 39% (↓ 27 to ↓ 50) Cmax: ↓ 29% (↓ 15 to ↓ 40) Cmin: ↓ 46% (↓ 31 to ↓ 58)
Slovenian: AUC: ↓ 39 % (↓ 27 do ↓ 50) Cmax: ↓ 29 % (↓ 15 do ↓ 40) Cmin: ↓ 46 % (↓ 31 do ↓ 58)
English: Co-administration of simeprevir with Atripla is not recommended.
Slovenian: Sočasne uporabe simeprevirja z zdravilom Atripla ne priporočamo.
English: AUC: ↓ 37% (↓ 14 to ↓ 55) Cmax: ↓ 35% (↓ 12 to ↓ 52) Cmin: ↓ 43% (↓ 18 to ↓ 60)
Slovenian: AUC: ↓ 37 % (↓ 14 do ↓ 55) Cmax: ↓ 35 % (↓ 12 do ↓ 52) Cmin: ↓ 43 % (↓ 18 do ↓ 60)
English: The following side effects are uncommon (these may affect up to 1 in every 100 patients):
Slovenian: Naslednji neželeni učinki so občasni (pojavijo se lahko pri največ 1 od 100 bolnikov):
English: Lopinavir/Ritonavir:
Slovenian: lopinavir/ritonavir: AUC: ↔
English: AUC: ↓ 34% (↓ 21 to ↓ 41) Cmax: ↓ 20% (↓ 2 to ↓ 26)
Slovenian: AUC: ↓ 34 % (↓ 21 do ↓ 41) Cmax: ↓ 20 % (↓ 2 do ↓ 26)
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 4.4).
Slovenian: Pri bolnikih z zmerno ali hudo ledvično insuficienco je potrebna prilagoditev intervala odmerjanja emtricitabina in dizoproksiltenofovirata, ki je ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 4.4).
English: AUC: ↓ 55% (↓ 48 to ↓ 62) Cmax: ↓ 34% (↓ 21 to ↓ 47)
Slovenian: AUC: ↓ 55 % (↓ 48 do ↓ 62) Cmax: ↓ 34 % (↓ 21 do ↓ 47)
English: Each Atripla film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as fumarate).
Slovenian: Ena filmsko obložena tableta zdravila Atripla vsebuje 600 mg efavirenza, 200 mg emtricitabina in 245 mg dizoproksiltenofovirata (v obliki fumarata).
English: Atazanavir/ritonavir/Emtricitabine
Slovenian: atazanavir/ritonavir/emtricitabin
English: Ritonavir/Emtricitabine
Slovenian: ritonavir/emtricitabin
English: Dosage adjustment of lopinavir/ritonavir is necessary when given with efavirenz.
Slovenian: Pri uporabi z efivarenzom je treba prilagoditi odmerek lopinavirja/ritonavirja.
English: General disorders and administration site conditions: Very common asthenia
Slovenian: Splošne težave in spremembe na mestu aplikacije: Zelo pogosti astenija
English: AUC: ↓ 43% (↓ 34 to ↓ 50) Cmax: ↓ 12% (↓ 1 to ↓ 26)
Slovenian: AUC: ↓ 43 % (↓ 34 do ↓ 50) Cmax: ↓ 12 % (↓ 1 do ↓ 26)
English: Rifampicin/Efavirenz (600 mg q.d./600 mg q.d.)
Slovenian: rifampicin/efavirenz (600 mg dnevno/600 mg dnevno)
English: The pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
Slovenian: Farmakokinetike zdravila Atripla pri bolnikih z jetrno okvaro niso raziskovali.
English: Rifampicin/Emtricitabine
Slovenian: rifampicin/emtricitabin
English: Atripla and fosamprenavir/ritonavir can be co-administered without dose adjustment.
Slovenian: Zdravilo Atripla in fosamprenavir/ritonavir se lahko uporabljata sočasno.
English: Itraconazole/Emtricitabine
Slovenian: itrakonazol/emtricitabin
English: Cmin: ↓ 12% (↓ 24 to ↑ 1)
Slovenian: Cmin: ↓ 12 % (↓ 24 do ↑ 1) (indukcija CYP3A4)
English: AUC: ↔*/** (↓ 10% to ↑ 26%) Cmax: ↔*/** (↓ 5% to ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 to ↑ 49)
Slovenian: AUC: ↔*/** (↓ 10 % do ↑ 26 %) Cmax: ↔*/** (↓ 5 % do ↑ 26 %) Cmin: ↑ 12 %*/** (↓ 16 do ↑ 49) (indukcija CYP3A4) *V primerjavi z atazanavirjem 300 mg/ritonavirjem 100 mg dnevno zvečer brez efavirenza.
English: Atorvastatin/Emtricitabine
Slovenian: atorvastatin/emtricitabin
English: AUC: ↓ 38% (↓ 28 to ↓ 47) Cmax: ↓ 32% (↓ 15 to ↓ 46) Cmin: ↓ 45% (↓ 31 to ↓ 56)
Slovenian: AUC: ↓ 38 % (↓ 28 do↓ 47) Cmax: ↓ 32 % (↓ 15 do ↓ 46) Cmin: ↓ 45 % (↓ 31 do ↓ 56)
English: Lopinavir/ritonavir/Emtricitabine
Slovenian: lopinavir/ritonavir/emtricitabin
English: AUC: ↔ Cmax: ↔ Cmin: ↔
Slovenian: emtricitabin: AUC: ↔ Cmax: ↔ Cmin: ↔
English: Co-administration of Atripla with sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is not recommended (see section 4.4).
Slovenian: Sočasne uporabe zdravila Atripla in sofosbuvirja/velpatasvirja ali sofosbuvirja/velpatasvirja/ voksilaprevirja ne priporočamo (glejte poglavje 4.4).
English: Raltegravir/Tenofovir disoproxil (400 mg b.i.d./-)
Slovenian: raltegravir/ dizoproksiltenofovirat (400 mg dvakrat dnevno/-)
English: ANTICONVULSANTS Carbamazepine/Efavirenz (400 mg q.d./600 mg q.d.)
Slovenian: ANTIKONVULZIVI karbamazepin/efavirenz (400 mg dnevno/600 mg dnevno)
English: Carbamazepine/Emtricitabine
Slovenian: karbamazepin/emtricitabin
English: Indinavir/Tenofovir disoproxil (800 mg q8h/245 mg q.d.)
Slovenian: indinavir/ dizoproksiltenofovirat (800 mg vsakih 8 ur/245 mg dnevno)
English: Please refer to the Summary of Product Characteristics for the individual components for additional information regarding in vivo resistance with these medicinal products.
Slovenian: Za dodatne informacije glede odpornosti in vivo, prosimo, glejte Povzetek glavnih značilnosti zdravila za posamezne učinkovine tega zdravila.
English: Boceprevir/Efavirenz (800 mg q8h/600 mg q.d.)
Slovenian: boceprevir/efavirenz (800 mg vsakih 8 ur/600 mg dnevno)
English: Atripla can reduce the amount of itraconazole or posaconazole in your blood.
Slovenian: Zdravilo Atripla lahko zniža količino itrakonazola ali pozakonazol v krvi.
English: Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil and with risk factors for renal dysfunction.
Slovenian: Pri bolnikih, zdravljenih z dizoproksiltenofoviratom, in z dejavniki tveganja za ledvično disfunkcijo so po uvedbi velikih odmerkov ali več nesteroidnih protivnetnih zdravil (NSAID) poročali o primerih akutne ledvične odpovedi.
English: Atovaquone and proguanil hydrochloride/Efavirenz (250/100 mg single dose/600 mg q.d.)
Slovenian: atovakvon in progvanil hidroklorid/efavirenz (250/100 mg posamezen odmerek/600 mg dnevno)
English: Atripla
Slovenian: Dojenje
English: AUC12h: ↔ Cmax: ↔
Slovenian: AUC12h: ↔
English: AUC: ↑ 21% (↑ 10 to ↑ 34) Cmax: ↑ 14% (↑ 4 to ↑ 26) Cmin: ↑ 25% (↑ 7 to ↑ 46)
Slovenian: AUC: ↑ 21 % (↑ 10 do ↑ 34) Cmax: ↑ 14 % (↑ 4 do ↑ 26) Cmin: ↑ 25 % (↑ 7 do ↑ 46) (zaviranje oksidativne presnove, pri kateri sodelujejo encimi CYP)
English: Maraviroc/Emtricitabine
Slovenian: maravirok/emtricitabin
English: (CYP3A4 or P-gp induction - effect on elbasvir)
Slovenian: Cmax: ↓ 45 % (indukcija CYP3A4 ali P-gp - učinek na elbasvir)
English: In general, emtricitabine pharmacokinetics in HBV infected patients were similar to those in healthy subjects and in HIV infected patients.
Slovenian: Farmakokinetike emtricitabina niso raziskovali pri bolnikih z različnimi stopnjami jetrne insuficience, ki niso okuženi z virusom HBV. Na splošno je bila farmakokinetika emtricitabina pri bolnikih, okuženih z virusom HBV, podobna tisti pri zdravih osebah in bolnikih, okuženih z virusom HIV.
English: As a fixed combination, Atripla should not be administered concomitantly with other medicinal products containing the components, emtricitabine or tenofovir disoproxil.
Slovenian: Zdravilo Atripla je zdravilo s fiksno kombinacijo odmerkov, zato se ne sme uporabljati sočasno z drugimi zdravili, ki vsebujejo učinkovini emtricitabin ali dizoproksiltenofovirat.
English: Voriconazole/Emtricitabine
Slovenian: vorikonazol/emtricitabin
English: Atovaquone and proguanil hydrochloride/Tenofovir disoproxil
Slovenian: atovakvon in progvanil hidroklorid/ dizoproksiltenofovirat
English: Indinavir/Emtricitabine (800 mg q8h/200 mg q.d.)
Slovenian: indinavir/emtricitabin (800 mg vsakih 8 ur/200 mg dnevno)
English: A single 245 mg dose of tenofovir disoproxil was administered to non-HIV infected patients with varying degrees of hepatic impairment defined according to CPT classification.
Slovenian: Bolnikom brez okužbe z virusom HIV z različnimi stopnjami jetrne okvare po klasifikaciji CPT so dali 245-miligramski odmerek dizoproksiltenofovirata.
English: Your doctor may give you a different anticonvulsant.
Slovenian: Zdravnik vam bo morda moral predpisati drug antimikotik.
English: Atripla [outer packaging only]
Slovenian: PODATKI V BRAILLOVI PISAVI Atripla [samo zunanja ovojnina]
English: Rifabutin/Tenofovir disoproxil
Slovenian: rifabutin/ dizoproksiltenofovirat
English: Common fatigue pain, asthenia
Slovenian: Pogosti utrujenost bolečina, astenija
English: Fosamprenavir/ritonavir/Tenofovir disoproxil
Slovenian: fosamprenavir/ritonavir/ dizoproksiltenofovirat
English: AUC: ↓ 31% (↓ 8 to ↓ 47) Cmin: ↓ 40%
Slovenian: AUC: ↓ 31 % (↓ 8 do ↓ 47)
English: Darunavir/ritonavir/Emtricitabine
Slovenian: darunavir/ritonavir/emtricitabin
English: Inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes caused death, have been reported rarely when medicines containing tenofovir disoproxil and didanosine were taken together.
Slovenian: Pri sočasnem jemanju zdravil, ki vsebujejo dizoproksiltenofovirat in didanozin, so redko poročali o vnetju trebušne slinavke in laktacidozi (zvišanje mlečne kisline v krvi), ki sta lahko bili tudi smrtni.
English: Dosage adjustments of simvastatin may be required when co-administered with Atripla (refer to the Summary of Product Characteristics for simvastatin).
Slovenian: Pri sočasni uporabi simvastatina z zdravilom Atripla bo morda potrebno prilagoditi odmerek simvastatina (glejte povzetek glavnih značilnosti zdravila za simvastatin).
English: AUC: ↓ 27% (↓ 20 to ↓ 33) Cmax: ↓ 20% (↓ 15 to ↓ 24) Cmin: ↓ 35% (↓ 24 to ↓ 44)
Slovenian: AUC: ↓ 27 % (↓ 20 do ↓ 33) Cmax: ↓ 20 % (↓ 15 do ↓ 24) Cmin: ↓ 35 % (↓ 24 do ↓ 44) efavirenz:
English: AUC: ↓ 77% Cmax: ↓ 61%
Slovenian: vorikonazol: AUC: ↓ 77 % Cmax: ↓ 61 %
English: Atazanavir/ritonavir/Efavirenz (400 mg q.d./100 mg q.d./600 mg q.d., all administered with food)
Slovenian: atazanavir/ritonavir/efavirenz (400 mg dnevno/100 mg dnevno/600 mg dnevno, vse zaužite s hrano)
English: Simeprevir/Tenofovir disoproxil (150 mg q.d./245 mg q.d.)
Slovenian: simeprevir/ dizoproksiltenofovirat (150 mg dnevno/245 mg dnevno)
English: Hepatic events
Slovenian: Jetrni dogodki
English: AUC: ↑ 34% (↑ 18 to ↑ 53) Cmax: ↑ 49% (↑ 32 to ↑ 69)
Slovenian: klaritromicin 14-hidroksimetabolit: AUC: ↑ 34 % (↑ 18 do ↑ 53) Cmax: ↑ 49 % (↑ 32 do ↑ 69)
English: Pregnancy should be avoided in women receiving Atripla.
Slovenian: Med jemanjem zdravila Atripla ženske ne smejo zanositi.
English: Atazanavir/ritonavir/Efavirenz (400 mg q.d./200 mg q.d./600 mg q.d., all administered with food)
Slovenian: atazanavir/ritonavir/efavirenz (400 mg dnevno/200 mg dnevno/600 mg dnevno, vse zaužite s hrano)
English: Rifampicin/Tenofovir disoproxil (600 mg q.d./245 mg q.d.)
Slovenian: rifampicin/ dizoproksiltenofovirat (600 mg dnevno/245 mg dnevno)
English: Pravastatin/Emtricitabine
Slovenian: pravastatin/emtricitabin
English: Etonogestrel/Tenofovir disoproxil
Slovenian: etonogestrel/ dizoproksiltenofovirat
English: CARDIOVASCULAR AGENTS Calcium Channel Blockers Diltiazem/Efavirenz (240 mg q.d./600 mg q.d.)
Slovenian: ZDRAVILA ZA ZDRAVLJENJE BOLEZNI SRCA IN OŽILJA Zaviralci kalcijevih kanalčkov diltiazem/efavirenz (240 mg dnevno/600 mg dnevno)
English: Indinavir/Efavirenz (800 mg q8h/200 mg q.d.)
Slovenian: indinavir/efavirenz (800 mg vsakih 8 ur/200 mg dnevno)